Funding has been awarded to principal investigator Dr. Melissa Mugambi, MD, PhD by the Bill and Melinda Gates Foundation for "Evaluating and optimizing a virtual care model for PrEP delivery."
Update: In 2022, Dr. Monisha Sharma assumed the role of Principal Investigator.
Abstract:
Dr. Mugambi will partner with an e-pharmacy and an implementing organization in Kenya to jointly develop and evaluate an end-to-end platform to support a client to initiate and continue PrEP through a virtual care model. The specific PrEP products to be delivered through this platform include TDF/FTC daily oral PrEP and Dapivirine Ring, with consideration to support the delivery of a monthly oral formulation after 2024 if Islatravir proves safe and efficacious in phase 3 trial.
April 3, 2023: Chen Y, Saldarriaga EM, Montano MA, et al. Assessing preferences for HIV pre-exposure prophylaxis (PrEP) delivery services via online pharmacies in Kenya: protocol for a discrete choice experiment. BMJ Open 2023;13:e069195. doi: 10.1136/bmjopen-2022-069195
May 8, 2023: POSTER "Preferences for online pre-exposure prophylaxis delivery among potential clients in Kenya: a discrete choice experiment"; presented at ISPOR 2023